[EN] 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 4,4-DISUBSTITUÉE
申请人:HOFFMANN LA ROCHE
公开号:WO2008145524A2
公开(公告)日:2008-12-04
[EN] This invention relates to 4,4-disubstituted piperidine derivatives of the formula (I) wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5. [FR] Cette invention concerne des dérivés de pipéridine 4,4-disubstituée de la formule (I), dans laquelle A et R1 à R5 sont tels que définis dans la description, et sont les sels pharmaceutiquement acceptables des dérivés. L'invention porte en outre sur des compositions pharmaceutiques contenant de tels composés, sur un procédé pour leur préparation et sur leur utilisation pour le traitement et/ou la prévention de maladies liées à la modulation du sous-type 5 des récepteurs SST.
4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES
申请人:Christ Andreas D.
公开号:US20080293756A1
公开(公告)日:2008-11-27
This invention relates to 4,4-disubstituted piperidine derivatives of the formula
wherein A and R
1
to R
5
are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
This invention relates to 4,4-disubstituted piperidine derivatives of the formula
wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.